Repare Therapeutics jumps on cancer drug licensing deal
ReutersJul 15, 2025 8:23 PM
** Shares of drug developer Repare Therapeutics RPTX.O rise 18% to $1.68 in extended trading
** RPTX licensed its cancer drug, lunresertib, to Swiss-based private firm Debiopharm for worldwide development and commercialization
** RPTX will receive $10 million upfront and could earn up to $257 million in milestone payments and royalties
** Debiopharm plans to combine lunresertib with its own drug Debio 0123 for cancer treatment
** Stock up 9.2% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Bitcoin Price Forecast: Trends and Investment Outlook from 2025 to 2030
From $0.01 in 2009 to $120,000+ in 2025, Bitcoin has evolved from obscurity to a globally recognized financial asset. While institutions and governments increasingly embrace it, investors must remain vigilant against volatility, security risks, and scams.TradingKey
Wed, Jul 16
What is the Future of Stablecoins? Here are Some Stablecoin Stocks to Watch
With regulations solidifying, institutional money flowing in, and global market expansion accelerating, stablecoin-related stocks could experience unprecedented growth.TradingKey
Wed, Jun 11
What Is the GENIUS Act, and Why Is Its Impact Comparable to a Bitcoin Spot ETF?
The GENIUS Act represents a groundbreaking federal regulatory framework for U.S. stablecoins, defining legal issuance standards, oversight responsibilities, consumer protections, and reserve requirements. While its primary objective is to advance U.S. financial interests, it will significantly shaTradingKey
Fri, May 30
[IN-DEPTH ANALYSIS] UnitedHealth (UNH): Can the Healthcare Giant Recover After Its Epic Collapse?
Once a Wall Street sweetheart, UnitedHealth Group (UNH) dominated the US healthcare industry with its unbeatable vertical empire, spanning insurance, clinics, pharmacies, and data analytics.TradingKey
Mon, May 26
.jpg)
Wells Fargo Q1 2025: Is it a Fragile Fortress or a Mispriced Revival
TradingKey - Wells Fargo's (WFC) Q1 2025 results present a paradox: resiliency without momentum. Net income on the surface was up 6% year-over-year at $4.9 billion, which is $1.39 a diluted share for a 16% EPS lift driven by forceful share repurchases.TradingKey
Thu, May 1
Tradingkey
